Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-type Human Alpha-synuclein

Overview

Journal J Neurosci

Specialty Neurology

Date 2004 Oct 22

PMID 15496679

Citations 253

Authors

Sheila M Fleming

Jonathan Salcedo

Pierre-Olivier Fernagut

Edward Rockenstein

Eliezer Masliah

Michael S Levine

Marie-Francoise Chesselet

Affiliations

Soon will be listed here.

Abstract

Accumulation of alpha-synuclein in brain is a hallmark of synucleinopathies, neurodegenerative diseases that include Parkinson's disease. Mice overexpressing alpha-synuclein under the Thy-1 promoter (ASO) show abnormal accumulation of alpha-synuclein in cortical and subcortical regions of the brain, including the substantia nigra. We examined the motor deficits in ASO mice with a battery of sensorimotor tests that are sensitive to alterations in the nigrostriatal dopaminergic system. Male wild-type and ASO mice were tested every 2 months for 8 months for motor performance and coordination on a challenging beam, inverted grid, and pole, sensorimotor deficits in an adhesive removal test, spontaneous activity in a cylinder, and gait. Fine motor skills were assessed by the ability to grasp cotton from a bin. ASO mice displayed significant impairments in motor performance and coordination and a reduction in spontaneous activity as early as 2 months of age. Motor performance and coordination impairments became progressively worse with age and sensorimotor deficits appeared at 6 months. Fine motor skills were altered at 4 months and worsened at 8 months. These data indicate that overexpression of alpha-synuclein induced an early and progressive behavioral phenotype that can be detected in multiple tests of sensorimotor function. These behavioral deficits provide a useful way to assess novel drug therapy in genetic models of synucleinopathies.

Citing Articles

Deciphering motor dysfunction and microglial activation in mThy1--synuclein mice: a comprehensive study of behavioral, gene expression, and methylation changes.

McGregor B, Raihan M, Brishti A, Hur J, Porter J Front Mol Neurosci. 2025; 18:1544971.

PMID: 40018011 PMC: 11865073. DOI: 10.3389/fnmol.2025.1544971.

Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease.

Sheta R, Berard M, Musiol D, Martinez-Drudis L, Oueslati A Front Aging Neurosci. 2025; 16:1464706.

PMID: 39763579 PMC: 11701160. DOI: 10.3389/fnagi.2024.1464706.

Methylphenidate differentially affects the social ultrasonic vocalizations of wild-type and prodromal Parkinsonian rats.

Lechner S, Kelm-Nelson C, Ciucci M Behav Neurosci. 2024; 139(1):1-9.

PMID: 39509189 PMC: 11747832. DOI: 10.1037/bne0000610.

Aging, Parkinson's Disease, and Models: What Are the Challenges?.

Rocha E, Chamoli M, Chinta S, Andersen J, Wallis R, Bezard E Aging Biol. 2024; 1.

PMID: 38978807 PMC: 11230631. DOI: 10.59368/agingbio.20230010.

No Evidence of Sensory Neuropathy in a Traditional Mouse Model of Idiopathic Parkinson's Disease.

Faisal M, Rusetskaya A, Vali L, Taba P, Minajeva A, Hickey M Cells. 2024; 13(10.

PMID: 38786023 PMC: 11120514. DOI: 10.3390/cells13100799.

References

Carter R, Lione L, Humby T, Mangiarini L, Mahal A, Bates G . Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 1999; 19(8):3248-57. PMC: 6782264. View

Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A . Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000; 287(5456):1265-9. DOI: 10.1126/science.287.5456.1265. View

Schallert T, Fleming S, Leasure J, Tillerson J, Bland S . CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000; 39(5):777-87. DOI: 10.1016/s0028-3908(00)00005-8. View

Rossini P, Filippi M, Vernieri F . Neurophysiology of sensorimotor integration in Parkinson's disease. Clin Neurosci. 2000; 5(2):121-30. View

van der Putten H, Wiederhold K, Probst A, Barbieri S, Mistl C, Danner S . Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000; 20(16):6021-9. PMC: 6772584. View

Sedelis M, Hofele K, Auburger G, Morgan S, Huston J, Schwarting R . MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet. 2000; 30(3):171-82. DOI: 10.1023/a:1001958023096. View

Hofele K, Sedelis M, Auburger G, Morgan S, Huston J, Schwarting R . Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp Neurol. 2001; 168(1):116-22. DOI: 10.1006/exnr.2000.7588. View

Tillerson J, Cohen A, Philhower J, Miller G, Zigmond M, Schallert T . Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci. 2001; 21(12):4427-35. PMC: 6762734. View

Dluzen D, Gao X, Story G, Anderson L, Kucera J, Walro J . Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp Neurol. 2001; 170(1):121-8. DOI: 10.1006/exnr.2001.7698. View

10.

Szczypka M, Kwok K, Brot M, Marck B, Matsumoto A, Donahue B . Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron. 2001; 30(3):819-28. DOI: 10.1016/s0896-6273(01)00319-1. View

11.

Sedelis M, Schwarting R, Huston J . Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001; 125(1-2):109-25. DOI: 10.1016/s0166-4328(01)00309-6. View

12.

Fernagut P, Diguet E, Labattu B, Tison F . A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 2002; 113(2):123-30. DOI: 10.1016/s0165-0270(01)00485-x. View

13.

Menalled L, Chesselet M . Mouse models of Huntington's disease. Trends Pharmacol Sci. 2002; 23(1):32-9. DOI: 10.1016/s0165-6147(00)01884-8. View

14.

Perez R, Waymire J, Lin E, Liu J, Guo F, Zigmond M . A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 2002; 22(8):3090-9. PMC: 6757524. DOI: 20026307. View

15.

Richfield E, Thiruchelvam M, Cory-Slechta D, Wuertzer C, Gainetdinov R, Caron M . Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol. 2002; 175(1):35-48. DOI: 10.1006/exnr.2002.7882. View

16.

Rockenstein E, Mallory M, Hashimoto M, Song D, Shults C, Lang I . Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002; 68(5):568-78. DOI: 10.1002/jnr.10231. View

17.

Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon H, Brundin P . Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem. 2002; 277(41):38884-94. DOI: 10.1074/jbc.M205518200. View

18.

Tillerson J, Cohen A, Caudle W, Zigmond M, Schallert T, Miller G . Forced nonuse in unilateral parkinsonian rats exacerbates injury. J Neurosci. 2002; 22(15):6790-9. PMC: 6758159. DOI: 20026651. View

19.

Menalled L, Sison J, Wu Y, Olivieri M, Li X, Li H . Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci. 2002; 22(18):8266-76. PMC: 6758087. View

20.

Lotharius J, Brundin P . Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet. 2002; 11(20):2395-407. DOI: 10.1093/hmg/11.20.2395. View